<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849576</url>
  </required_header>
  <id_info>
    <org_study_id>VIAject™-15J</org_study_id>
    <nct_id>NCT00849576</nct_id>
  </id_info>
  <brief_title>Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of insulin VIAject with Regular Human
      Insulin and Insulin Lispro on measures of mealtime blood vessel stress and blood flow.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.</measure>
    <time_frame>0 - 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.</measure>
    <time_frame>0 - 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Regular Human Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inuslin Lispro (90%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin VIAject™ (75%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin VIAject™ (90%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Human Insulin</intervention_name>
    <description>0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.</description>
    <arm_group_label>Regular Human Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.</description>
    <arm_group_label>Inuslin Lispro (90%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin VIAject™ (75%)</intervention_name>
    <description>75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal</description>
    <arm_group_label>Insulin VIAject™ (75%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin VIAject™ (90%)</intervention_name>
    <description>90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal</description>
    <arm_group_label>Insulin VIAject™ (90%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes mellitus according to the ADA criteria

          2. HbA1c between 6.5 % and 9.9 %

          3. Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3
             months

          4. Age between 40 and 75 years

          5. BMI &lt; 40

        Exclusion Criteria:

          1. Type 1 diabetes mellitus

          2. Pre-treatment with insulin within the last 6 months prior to screening

          3. Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks
             prior to screening

          4. Untreated hypertension stage II-III according to WHO criteria

          5. Planned or anticipated change in antidiabetic and/or concomitant medication during
             study participation

          6. Total cholesterol &gt; 300 mg/dl (anamnestically)

          7. Major micro- or macrovascular complications as judged by the investigator

          8. Tobacco use within the last 6 months prior to screening

          9. Drugs with major impact on endothelial function like nitrates etc.

         10. History of drug or alcohol abuse which in the opinion of the investigator will impair
             subject safety or protocol compliance

         11. History of hypersensitivity to the study drugs or to drugs with similar chemical
             structures

         12. History of severe or multiple allergies

         13. Treatment with any other investigational drug within 3 months prior to screening

         14. Progressive fatal disease

         15. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT
             and/or ASAT &gt; 3 times the normal reference range), renal (creatinine &gt; 1.1 mg/dL in
             women and &gt; 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease
             as judged by the investigator

         16. Pregnancy or breast feeding

         17. Sexually active women of childbearing potential not consistently and correctly
             practicing birth control by implants, injectables, oral contraceptives, hormonal
             intrauterine devices (IUDs), sexual abstinence or vasectomised partner

         18. Lack of compliance or other similar reason that at the discretion of the investigator
             precludes satisfactory participation in the study

         19. Hypopotassemia (K&lt;3.5 mmol /l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKFE Institute for Clinical Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IKFE</name>
      <address>
        <city>Parcusstrasse 8</city>
        <state>Mainz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <disposition_first_submitted>July 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 3, 2015</disposition_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

